Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 4/20 | 0.44 |
| ▸ | SCTR | P47872 | 1/20 | 0.44 |
| ▸ | IL23R | Q5VWK5 | 9/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 3/20 | 0.40 |
| ▸ | NPY1R | P25929 | 2/20 | 0.40 |
| ▸ | NPY2R | P49146 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.40 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30931482 | 0.91 | NPY4R (0.43) | APLNRC5AR1KLK7NPY4RNPY1R | |
| SCHEMBL30262026 | 0.90 | VIPR2 (0.51) | GLP1RSCTRIL23RVIPR2 | |
| SCHEMBL30168704 | 0.90 | VIPR2 (0.51) | GLP1RSCTRIL23RC5AR1VIPR2 | |
| SCHEMBL29836212 | 0.88 | IL23R (0.51) | GLP1RSCTRIL23RVIPR2 | |
| SCHEMBL31548692 | 0.88 | GLP1R (0.48) | GLP1RAPLNRVIPR2 | |
| SCHEMBL30390767 | 0.87 | NPY4R (0.46) | APLNRC5AR1NPY4RNPY1RNPY2R | |
| SCHEMBL31501130 | 0.87 | APLNR (0.41) | GLP1RSCTRIL23RAPLNRC5AR1 | |
| SCHEMBL31353031 | 0.86 | GLP1R (0.51) | GLP1RSCTR | |
| SCHEMBL31165493 | 0.86 | NPY4R (0.41) | GLP1RSCTRAPLNRC5AR1NPY4R | |
| SCHEMBL30790301 | 0.85 | NPY4R (0.43) | APLNRNPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589064-B2 | Trolox-peptide conjugate and use thereof | CAREGEN CO., LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| EP-3967327-B1 | TROLOX-PEPTIDE CONJUGATE AND USE THEREOF | CAREGEN CO LTD (KR) | 2026-01-07 | — | — | EP | disclosed |
| CN-114007579-B | Trolox-peptide conjugates and uses thereof | 凯尔格恩有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230181441-A1 | TROLOX-PEPTIDE CONJUGATE AND USE THEREOF | CAREGEN CO., LTD. (KR) | 2023-06-15 | — | — | US | disclosed |
| US-11617796-B2 | Conjugate of minoxidil and peptide | CAREGEN CO., LTD. (KR) | 2023-04-04 | — | — | US | disclosed |
| EP-3501545-B1 | CONJUGATE OF MINOXIDIL AND PEPTIDE | CAREGEN CO LTD (KR) | 2022-10-26 | — | — | EP | disclosed |
| US-11357783-B2 | Conjugate of finasteride with peptide | CAREGEN CO., LTD. (KR) | 2022-06-14 | — | — | US | disclosed |
| EP-3967327-A2 | TROLOX-PEPTIDE CONJUGATE AND USE THEREOF | Caregen Co., Ltd. (KR) | 2022-03-16 | — | — | EP | disclosed |
| CN-114007579-A | Trolox-peptide conjugates and uses thereof | 凯尔格恩有限公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357783-B2 | Conjugate of finasteride with peptide | CYP17A1, SHBG, PSAP | GLP1R 245/4885SCTR 1247/4885IL23R 331/4885 |
| US-11617796-B2 | Conjugate of minoxidil and peptide | TYR, FGF2, MC1R | GLP1R 527/4885SCTR 1350/4885IL23R 925/4885 |
| US-20230181441-A1 | TROLOX-PEPTIDE CONJUGATE AND USE THEREOF | PRDX3, TXNRD3, TXNRD2 | GLP1R 624/4885SCTR 1049/4885IL23R 307/4885 |
| US-12589064-B2 | Trolox-peptide conjugate and use thereof | CYP27B1, TEKT1, TXNRD2 | GLP1R 737/4885SCTR 554/4885IL23R 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.